NoneNoneNoneCharacteristics of patients with malignant pheochromocytoma. However, when FDA is unavailable, DOPA-PET or MIBG scintigraphy can be used as valid alternatives[None]. Another limitation is that pathologic data were not available to compare with the changes evident on MIBG imaging. Furthermore, CT and MR studies were not available in all patients for systematic comparison with the MIBG findings. Changes in overall MIBG uptake mirrored the change in urinary VMA excretion. 